| Object: To evaluate serum adiponectin distribution and its association with metabolic syndrome.Design: Cross-sectional and case control study.Methods: 111 MetS cases and 152 controls were measured serum adiponectin levels with sandwich ELISA.Results:①Serum adiponectin levels in men were significantly lower than those in women [4.44(0.97-16.55) vs. 7.59(1.29-23.29) ug/ml, P<0.001].The difference did not disappear after adjusted for BMI (P<0.001). No age-associated difference in serum adiponectin levels was observed.②Serum adiponectin concentrations were positively correlated with HDL-C and ANGPTL3 (P<0.05) after adjusted for age and sex. Serum adiponectin concentrations were negatively correlated with BMI, WC, WHR, fat percentage, FPG,TG,UA, FINS, HOMAIR, and hsCRP (P<0.05). TG, ANGPTL3, sex, and HOMA-IR were found to be independent determinants for serum adiponectin concentrations.③No difference in serum adiponectin levels was observed between the hypertension and the control group [(4.77(1.01-23.29) vs. 5.17(0.97-22.27) ug/ml, P=0.991)].④Serum adiponectin concentrations were lower in the obesity and overweight groups than in the lean group [4.34(1.61-15.09) vs. 4.28(0.97-22.27) vs. 5.99(1.16-23.29) ug/ml , P=0.001]. No difference in serum adiponectin levels was observed between the overweight and the obesity group.⑤Serum adiponectin concentrations were significantly lower in the hypertriglyceridemia than in the control group [4.40(0.97-23.29) vs. 6.67(1.12-22.27) ug/ml, P=0.001)]. Serum adiponectin concentrations were significantly lower in the hypo-high density lipoproteinemia than in the control group [4.96(0.97-14.88) vs. 5.18(1.12-23.29) ug/ml, P=0.005)].⑥Serum adiponectin concentrations were significantly lower in the T2DM than in the NGT and IGT groups [5.05(1.06-23.29) vs. 5.50(0.97-22.27) vs. 3.13(1.01-13.57) ug/ml, P<0.001]. No difference in serum adiponectin levels was observed between the NGT and the IGT groups.⑦Serum adiponectin concentrations were significantly lower in the hyperuricemia than in the control group [3.9(1.20-13.72) vs. 5.4(0.97-23.29) ug/ml, P=0.004].⑧Serum adiponectin concentrations were significantly lower in the NAFLD than in the control group [4.18(1.01-15.09) vs. 6.3(0.97-23.29) ug/ml, P<0.001].⑨Serum adiponectin concentrations were significantly lower in the metabolic syndrome than in the control group [4.22(1.01-23.29) vs. 5.41(0.97-22.27) ug/ml, P=0.002]. Serum adiponectin concentrations were all significantly lower in the metabolic syndrome than in the control group under different metabolic syndrome definitions. There were no differences in adiponectin levels among metabolic syndrome groups by different definitions (P=0.909) . Serum adiponectin concentrations were significantly lower with more metabolic disorders. In the highest adiponectin tertile, the MetS risk was significantly lower than in the lowest tertile.Conclusion: Each component of metabolic syndrome, except for blood pressure, showed significantly lower serum adiponectin concentrations for both men and women. Serum circulating adiponectin concentrations are decreased in human subjects with hyperuricemia. Object: To evaluate serum angiopoietin -like protein 3 (ANGFTL3) distributions and its association with metabolic syndrome.Design: Cross-sectional and case control study.Methods: 111 MetS cases and 152 controls were measured serum ANGPTL3 levels with sandwich ELISA.Results:①No gender-associated difference in serum ANGPTL3 levels was observed(418.84±140.90 vs. 437.22±160.46 ng/ml, P=0.384). Serum ANGPTL3 levels in men > 50 years were significantly higher than those <50 years.②Serum ANGPTL3 concentrations were positively correlated with adiponectin (P<0.05) after adjusted for age and sex. Serum ANGPTL3 concentrations were negatively correlated with FINS and HOMA-IR (P<0.05). Adiponectin was found to be independent determinant for serum ANGPTL3 concentrations.③No difference in serum ANGPTL3 levels was observed between the hypertension and the control group (423.96±143.17 vs. 421.24±153.72 ng/ml, P=0.894).④Serum ANGPTL3 concentrations were lower in the overweight group than in the lean and obesity group (453.51±145.28 vs. 380.47±127.80 vs. 450.73±161.37ng/ml,P<0.001).⑤Serum ANGPTL3 concentrations were no significantly difference between hypertriglyceridemia and control group (424.69±154.06 vs. 421.92±138.16ng/ml, P=0.878). No difference in serum ANGPTL3 levels was observed between the hypo-high density lipoproteinemia and the control group (428.46±134.06 vs. 416.94±158.81 ng/ml, P=0.531).⑥No difference in serum ANGPTL3 levels was observed among NGT, IGT and T2DM groups.⑦No difference in serum ANGPTL3 levels was observed between the hyperuricemia and the control group (428.48±144.52 vs. 409.09±138.0ng/ml, P=0.374).⑧No difference in serum ANGPTL3 levels was observed between the NAFLD and the control group (414.19±143.67 vs. 435.41±144.58 ng/ml, P=0.256).⑨No difference in serum ANGPTL3 levels was observed between the metabolic syndrome and the control group (418.81±148.45 vs. 426.49±144.10 ng/ml, P=0.674).Conclusions: Serum ANGPTL3 concentrations were independently positively correlated with adiponectin, but not correlated with TG and HDL-C. Object: To evaluate serum Retinol-binding protein 4 (RBP4) distributions and its association with metabolic syndrome.Design: Cross-sectional and case control study.Methods: 111 MetS cases and 152 controls were measured serum RBP4 levels with sandwich ELISA.Results:①Serum RBP4 levels in men were significantly higher than those in women (54.11±17.08 vs. 38.72±12.46 ug/ml, P<0.001). No age-associated difference in serum RBP4 levels was observed.②Serum RBP4 concentrations were positively correlated with BMI, WC, WHR, PBG,TG,CHOL, LDL, SBP, DBP, FINS, HOMA-IR, fat percentage and UA(P<0.05)after adjusted for sex and age. Serum RBP4 concentrations were negatively correlated with HDL-C (P<0.05). TG,sex(male=1, female=2), DBP and UA were found to be independent determinants for serum RBP4 concentrations.③Serum RBP4 concentrations were higher in the hypertension in men than the control group [61.96±19.16 vs. 51.28±15.38ug/ml, P<0.001].④Serum RBP4 concentrations were higher in the obesity and overweight groups than in the lean group (45.75±16.11 vs. 52.45±17.79 vs. 55.60±16.94ug/ml, P=0.026). No difference in serum RBP4 levels was observed between the overweight and the obesity group (P=0.274).⑤No difference in serum RBP4 levels was observed among the NGT, IGT and T2DM groups (50.10±20.04 vs. 48.38±14.67 vs. 53.96±19.23ug/ml, P=0.074).⑥Serum RBP4 concentrations were significantly higher in the hypertriglyceridemia than in the control group (55.22±17.72 vs. 45.21±17.72ug/ml, P<0.001).⑦Serum RBP4 concentrations were significantly higher in the hyperuricemia than in the control group (57.62±15.69 vs.48.43±16.88, P=0.032).⑧Serum RBP4 concentrations were significantly higher in the NAFLD than in the control group (55.22±17.99 vs. 47.44±15.24ug/ml, P=0.019).⑨Serum RBP4 concentrations were significantly higher in the_metabolic syndrome than in the control group (54.79±18.32 vs. 47.23±15.96 ug/ml , P=0.002). Serum RBP4 concentrations were all significantly higher in the metabolic syndrome than in the control group under different metabolic syndrome definitions. There was no difference in RBP4 levels among metabolic syndrome groups by different definitions. Serum RBP4 concentrations were significantly higher with more metabolic disorders. In the highest RBP4 tertile, the MetS risk was significantly higher than in the lowesttertile.Conclusion: Each component of metabolic syndrome, except forblood glucose, showed significantly higher serum RBP4 concentrations for both men and women.serum circulating RBP4 concentrations are elevated in human subjects with hyperuricemia. Serum circulating RBP4 concentrations are elevated in human subjects with NAFLD. Object: To evaluate serum lipocalin 2 (LCN2) distributions and its association with metabolic syndrome.Design: Cross-sectional and case control study.Methods: 111 MetS cases and 152 controls were measured serum LCN2 levels with sandwich ELISA.Results:①No gender, sex-associated difference in serum LCN2 levels was observed.②Serum LCN2 concentrations were positively correlated with BMI, WC, fat percentage, and hsCRP (P<0.05) after adjusted for sex and age. Serum LCN2 concentrations were negatively correlated with HDL-C (P<0.05). HDL-C and hsCRP were found to be independent determinants for serum LCN2 concentrations.③No difference in serum LCN2 levels was observed between the hypertension and the control group [29.25(10.75-123.25) vs. 28(9.25-92.25) ug/L, P=0.741].④Serum LCN2 concentrations were higher in the obesity group than in the lean and overweight groups [36.37(13-123.25) vs. 29.0(10.75-82.50) vs. 26.75(9.25-86.5) ug/L, P=0.018]. No difference in serum LCN2 levels was observed between the overweight and the lean groups.⑤Serum LCN2 concentrations were no significantly difference between hypertriglyceridemia and control group [29.0(10.75-86.5) vs. 29.0(9.25-123.25)ug/L, P=0.676]. Serum LCN2 concentrations were significantly higher in the hypo-high density lipoproteinemia than the control group [32.62(9.75-82.50) vs. 26.37(9.25-123.25), P=0.001].⑥Serum LCN2 concentrations were higher in the IGT and T2DM groups than in the NGT group [32.5(9.75-89.5) vs. 32.25(9.25-92.25) vs. 27.0(10.75-123.25)ug/L, P=0.008].⑦No difference in serum LCN2 levels was observed between the hyperuricemia and the control group [29.12(9.25-130.25) vs. 30(13-123.25)ug/L, P=0.247].⑧No difference in serum ANGPTL3 levels was observed between the NAFLD and the control group [32.37(9.25-130.25) vs. 28.37(10.75-123.25)ug/L , P=0.134].⑨Serum LCN2 concentrations were significantly higher in the metabolic syndrome than in the control group [32.37(9.25-156.5) vs. 28(10.75-118.25) ug/L, P=0.032]. Serum LCN2 concentrations were all significantly higher in the metabolic syndrome than in the control group under different metabolic syndrome definitions. There was no difference in LCN2 levels among metabolic syndrome groups by different definitions.Conclusion: Serum LCN2 concentrations were higher in obesity, T2DM, and metabolic syndrome. Serum lipocalin-2 is independently positively correlated with hsCRP, and can be a useful new marker for evaluating inflammatory status in obesity and MetS.
|
PDF Full Text Request